195 related articles for article (PubMed ID: 10082200)
1. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist.
Iwasaki T; Mihara S; Shimamura T; Kawakami M; Hayasaki-Kajiwara Y; Naya N; Fujimoto M; Nakajima M
J Cardiovasc Pharmacol; 1999 Jul; 34(1):139-47. PubMed ID: 10413080
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic characterization of S-1255, a highly potent and orally active endothelin A receptor antagonist.
Iwasaki T; Mihara S; Shimamura T; Kawakami M; Masui M; Hayasaki-Kajiwara Y; Naya N; Ninomiya M; Fujimoto M; Nakajima M
J Cardiovasc Pharmacol; 2001 Apr; 37(4):471-82. PubMed ID: 11300660
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
Wessale JL; Adler AL; Novosad EI; Calzadilla SV; Dayton BD; Marsh KC; Winn M; Jae HS; von Geldern TW; Opgenorth TJ; Wu-Wong JR
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():112S-117S. PubMed ID: 12193067
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist.
Williams DL; Murphy KL; Nolan NA; O'Brien JA; Lis EV; Pettibone DJ; Clineschmidt BV; Krause SM; Veber DF; Naylor EM; Chakravarty PK; Walsh TF; Dhanoa DM; Chen A; Bagley SW; Fitch KJ; Greenlee WJ
Life Sci; 1996; 58(14):1149-57. PubMed ID: 8614266
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
Wu-Wong JR; Dixon DB; Chiou WJ; Sorensen BK; Liu G; Jae HS; Tasker A; von Geldern TW; Winn M; Opgenorth TJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():107S-111S. PubMed ID: 12193066
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
Clozel M; Ramuz H; Clozel JP; Breu V; Hess P; Löffler BM; Coassolo P; Roux S
J Pharmacol Exp Ther; 1999 Aug; 290(2):840-6. PubMed ID: 10411600
[TBL] [Abstract][Full Text] [Related]
13. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
Webb ML; Bird JE; Liu EC; Rose PM; Serafino R; Stein PD; Moreland S
J Pharmacol Exp Ther; 1995 Mar; 272(3):1124-34. PubMed ID: 7891325
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist.
Yuyama H; Sanagi M; Koakutsu A; Mori M; Fujimori A; Harada H; Sudoh K; Miyata K
Eur J Pharmacol; 2003 Sep; 478(1):61-71. PubMed ID: 14555186
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.
Douglas SA; Nambi P; Gellai M; Luengo JI; Xiang JN; Brooks DP; Ruffolo RR; Elliott JD; Ohlstein EH
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S273-6. PubMed ID: 9595458
[TBL] [Abstract][Full Text] [Related]
18. LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions.
Raschack M; Göck S; Unger L; Hahn A; Amberg W; Jansen R; Alken P; Weber A; Hergenröder S
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S241-4. PubMed ID: 9595449
[TBL] [Abstract][Full Text] [Related]
19. Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine.
Burke SE; Nelson RA; Lubbers NL; Ford TT; Fu KI; Padley RJ; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2000 Jun; 35(6):838-44. PubMed ID: 10836715
[TBL] [Abstract][Full Text] [Related]
20. Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.
Ksander GM; Shetty SS; DelGrande D; Balwierczak JL; Bruseo CW; Savage P; deJesus R; Yuan A; Webb RL; Jeng AY
Can J Physiol Pharmacol; 2002 May; 80(5):464-9. PubMed ID: 12056554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
